129 related articles for article (PubMed ID: 7307430)
1. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia.
Piroli RJ; Passananti GT; Shively CA; Vesell ES
Clin Pharmacol Ther; 1981 Dec; 30(6):810-6. PubMed ID: 7307430
[TBL] [Abstract][Full Text] [Related]
2. Ethnic differences in reactions to drugs and xenobiotics. Other protein variants with pharmacogenetic consequences: albumin and orosomucoid.
Alván G
Prog Clin Biol Res; 1986; 214():345-55. PubMed ID: 3523512
[No Abstract] [Full Text] [Related]
3. Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E; Bakke O; Ueland PM
Cancer Chemother Pharmacol; 1986; 18(3):270-5. PubMed ID: 2948732
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats.
Yacobi A; Levy G
J Pharm Sci; 1975 Oct; 64(10):1660-4. PubMed ID: 1195101
[TBL] [Abstract][Full Text] [Related]
5. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
[TBL] [Abstract][Full Text] [Related]
6. The effect of carbon tetrachloride (CCl4) induced liver damage on the volume of distribution, the elimination half-life and body clearance of antipyrine and warfarin in rabbits.
Ladefoged O
Acta Vet Scand; 1979; 20(3):429-37. PubMed ID: 506875
[TBL] [Abstract][Full Text] [Related]
7. Quinine-induced alterations in drug disposition.
Berlin CM; Stackman JM; Vesell ES
Clin Pharmacol Ther; 1975 Dec; 18(6):670-9. PubMed ID: 1204275
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors.
Ganeval D; Fischer AM; Barre J; Pertuiset N; Dautzenberg MD; Jungers P; Houin G
Clin Nephrol; 1986 Feb; 25(2):75-80. PubMed ID: 3698349
[TBL] [Abstract][Full Text] [Related]
9. Effects of albumin and alpha-1 acid glycoprotein on elimination of prazosin and antipyrine in the isolated perfused rat liver.
Oie S; Fiori F
J Pharmacol Exp Ther; 1985 Sep; 234(3):636-40. PubMed ID: 4032284
[TBL] [Abstract][Full Text] [Related]
10. Antipyrine disposition and liver size in the elderly.
Swift CG; Homeida M; Halliwell M; Roberts CJ
Eur J Clin Pharmacol; 1978 Nov; 14(2):149-52. PubMed ID: 720377
[TBL] [Abstract][Full Text] [Related]
11. Hypoalbuminemia as a risk factor for over-anticoagulation.
Tincani E; Mazzali F; Morini L
Am J Med; 2002 Feb; 112(3):247-8. PubMed ID: 11893361
[No Abstract] [Full Text] [Related]
12. Morphologic, biochemical and physiologic alterations in a case of idiopathic hypoalbuminemia (analbuminemia).
Weinstock JV; Kawanishi H; Sisson J
Am J Med; 1979 Jul; 67(1):132-9. PubMed ID: 463906
[TBL] [Abstract][Full Text] [Related]
13. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
[TBL] [Abstract][Full Text] [Related]
14. Antipyrine kinetics in undernourished diabetics.
Shobha JC; Raghuram TC; Kumar AD; Krishnaswamy K
Eur J Clin Pharmacol; 1991; 41(4):359-61. PubMed ID: 1804653
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of Cl2Ca and Cl2Mg on warfarin-human serum albumin (HSA) binding.
Pérez Gallardo L
Magnes Res; 1999 Mar; 12(1):43-8. PubMed ID: 10192099
[TBL] [Abstract][Full Text] [Related]
16. The effect of fenfluramine on disposition and rate of antipyrine elimination.
O'Malley K; Stevenson IH; West M
Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
[TBL] [Abstract][Full Text] [Related]
17. Antipyrine kinetics in Nigerian women in chronic renal failure.
Iyun AO; Tucker GT
Afr J Med Med Sci; 1982 Mar; 11(1):7-9. PubMed ID: 6291357
[TBL] [Abstract][Full Text] [Related]
18. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
19. Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.
Urien S; Albengres E; Pinquier JL; Tillement JP
Clin Pharmacol Ther; 1986 Jun; 39(6):683-9. PubMed ID: 3709033
[TBL] [Abstract][Full Text] [Related]
20. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
Lai CM; Moore P; Quon CY
Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
